Systemic AKT agonist infusions would also likely activate AKT in tumors, blocking the effectiveness of cyclophosphamide, unlike FGF7p or FGF7, given that lymphoma cells do not express FGFR2IIIb (Orr‐Urtreger et al., 1993). The gene discussed is AKT1; the disease is lymphoma.